Active, Not Recruiting
A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma - CA209-8HC
Updated: 3 October, 2018 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: - Patients must have ≥1 medical or pharmacy claim for nivolumab, ipilimumab, pembrolizumab, nivolumab+ipilimumab (on the same day), dabrafenib, vemurafenib, cobimetinib, trametinib, dabrafenib+trametinib (on the same day) and vemurafenib+cobimetinib (on the same day) - Patients must have ≥6 months of continuous health plan enrollment prior to index date - Patients must have ≥2 medical claims at least 30 days apart with a diagnosis for melanoma during the study period AND ≥1 diagnosis for melanoma during the baseline period prior to or on the index date Exclusion Criteria: - Patients with ≥1 claim for the agents of interest including immunotherapy agents and BRAF/MEK inhibitors between the first diagnosis of metastatic disease and the day prior to the index date will be excluded - Patients with a claim for acquired immunodeficiency virus (AIDS) anytime during the study period - Patients under the age of 18 as of index date Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
